The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.

@article{Patsalos2015TheCP,
  title={The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.},
  author={Philip N. Patsalos},
  journal={Epilepsia},
  year={2015},
  volume={56 1},
  pages={12-27}
}
The clinical pharmacology profile of a drug critically determines its therapeutics, and this review summarizes the characteristics associated with the antiepileptic drug (AED) perampanel. A PubMed literature search was performed for perampanel. Congress abstract data are included where necessary and Eisai Ltd provided access to unpublished data on file. After oral ingestion, perampanel is rapidly absorbed and peak plasma concentrations occur 0.5-2.5 h later; its bioavailability is ~100… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS
30 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

and Drug Administration FDA

  • US Foo
  • Clinical pharmacology and biopharmaceutics review…
  • 2014
Highly Influential
20 Excerpts

Perampanel (Fycompa). Summary of product characteristics

  • Fycompa SPC
  • Updated 13 November,
  • 2013
Highly Influential
10 Excerpts

Pharmacokinetics of perampanel: results from Phase I clinical studies

  • B Gidal, A Laurenza, H Yang
  • Poster presented at the 67th Annual Meeting of…
  • 2013
Highly Influential
6 Excerpts

Pharmacokinetics of perampanel: results from Phase I clinical pharmacology studies

  • B Gidal, A Laurenza, H Yang
  • Epilepsy Curr 2014;14:66:61.143
  • 2014

Similar Papers

Loading similar papers…